The U.S. pharmaceutical market is at a critical inflection point in early 2026. For decades, the industry has operated within a framework that, while fostering significant innovation, has also ...

Forbes contributors publish independent expert analyses and insights. I consult on marketing strategy, content creation, and messaging. The market is pricing Strategy (NASDAQ: MSTR), formerly ...

2026 has opened on a brutal note for crypto and even longtime Bitcoin believers are feeling the chill. On Feb. 3, Bitcoin (BTC) plunged below $73,000, marking its steepest decline since early November ...

This case study showcases how DelveInsight supported a leading Asian conglomerate in building a clear, evidence-backed roadmap for entering the rapidly evolving cell Imaging and analysis devices ...

Electronic shelf-edge labels (ESEL) are having their infrastructure moment. Most retailers still frame them as operational ...

Intel (INTC) stock analysis: 37 analysts issue mixed ratings as shares trade at $45.57. Q4 revenue fell 4% YoY. Is it time to buy or wait?